Bleomycin Inhibits CLEC14A to Attenuate the Progression of Extracranial Arteriovenous Malformations

Congzhen Qiao,Yajing Qiu,Yun Zou,Chen Hua,Yuanbo Li,Yunbo Jin,Xiaoxi Lin
DOI: https://doi.org/10.1016/j.cjprs.2021.12.005
2021-01-01
Chinese Journal of Plastic and Reconstructive Surgery
Abstract:Background: We previously reported that interstitial injection of bleomycin(BLM) reduces the size of early-stage extracranial arteriovenous malformation(AVM). Here, we sought to investigate the potential mechanism of BLM in treating extracranial AVM.Methods: Samples of human extracranial AVM(n=3) with no pharmacological treatment were harvested. AVM endothelial cells were isolated and cultured in primary cell culture. The transcriptome was examined using RNAsequencing, and differentially expressed C-type lectin domain family 14 member A(CLEC14 A) was validated at the transcriptomic and protein levels. Immunocytochemical staining of CLEC14 A was performed in samples of human extracranial AVM, with and without BLM treatment.Results: Through second-generation sequencing, we found that the expression of 5 689 genes were differentially increased or decreased following 24-h BLM stimulation. We found that CLEC14 A may play an important role in the progression of AVM and can be inhibited by BLM treatment.Conclusion: BLM inhibited CLEC14 A expression to attenuate the progression of AVM.
What problem does this paper attempt to address?